Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.